The long awaited Ebola vaccines are now in Liberia. At last, while they are still classified experimental, there’s now a possibility Ebola infection can be contained. The initial trial will consist of 300 volunteers, which is going to begin within few weeks, the British pharmaceutical company GlaxoSmithKline (GSK) said on Friday.
The first batch of trial vaccines, which are expected to arrive in Monrovia, Liberia’s capital on Friday, will be only be for health workers who are at present taking care of Ebola victims. The 300 doses will be expanded to 30 000 people all over this West African country.
One of several candidate vaccines tagged to fight Ebola infections, was tested involving 200 healthy volunteers in several countries such as Britain, the United States, Switzerland and Mali, according to GSK sources.
“Initial data from these trials show that the candidate vaccine has an acceptable safety profile, including in a West African population, and across the different doses evaluated,” the company said.
The experimental vaccine utilizes a chimpanzee cold virus type to act as the carrier to deliver attenuated strain from the Zaire Ebola virus, the perpetrator of the present epidemic. The number of infected people numbering 21,724 people worldwide killing more than 8,000 people. This figure was supplied by WHO.
Liberia is next to Sierra Leone, in the number of victims caused by Ebola virus infection with 8,478 cases, of these 3, 605 died according to World Health Organization. Sierra Leone on the other hand with 10,340 cases and the deaths numbering to 3, 145.
The number of people who were infected with Ebola virus has reached 21 724 worldwide, since the outbreak started in Guinea in December 2013, according to WHO.
Other drug companies are expected to follow suit with their own Ebola vaccine trial doses. If successful, mass production of these vaccines will follow in the months to come. The virus is very deadly and containing is the number one goal of the WHO right now.